Resultados de la búsqueda 371-380 of 15440 for disordered eating

  1. Mayo Clinic Physician Update - May 2025

    Page 1.

  2. Neurología - Ensayos clínicos - Mayo Clinic

    All participants will undergo baseline screening for evidence of pre-stroke dementia. Those who pass baseline screening will complete a blood draw and a series ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  4. Neurología - Ensayos clínicos - Mayo Clinic

    To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...

  5. Nutrición y comida saludable Multimedia - Mayo Clinic

    Add 5 habits. In: The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Dietary supplements: What you need to know. Office of Dietary Supplements. https://ods.

  6. Nutrición y comida saludable Healthy diets - Mayo Clinic

    Accessed June 13, 2023. Medical review (expert opinion). Mayo Clinic. June 21, 2023. Hensrud DD, ed. Add 5 habits. In: The Mayo Clinic Diet. 3rd ed. Mayo Clinic ...

  7. Nutrición y comida saludable Healthy diets - Mayo Clinic

    Add 5 habits. In: The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Dietary supplements: What you need to know. Office of Dietary Supplements. https://ods.

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

  9. Nutrición y comida saludable Nutrition basics - Mayo Clinic

    Mayo Clinic. June 21, 2023. Hensrud DD, ed. Add 5 habits. In: The Mayo Clinic Diet. 3rd ed. Mayo Clinic Press; 2023. Dietary supplements: What you need to know.

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...